ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.869,24
-0,11%
S&P 500
5.739,95
-0,09%
US Dollar vs BRL
5,4345
-0,07%
Bitcoin
65.683,82
0,77%
Brent Oil
71,955
1,42%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) Notícias

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:JNJ
DataHoraFonteTítuloCódigoCompanhia
27/09/202414:05PR Newswire (US)DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myelomaNYSE:JNJJohnson and Johnson
27/09/202414:00PR Newswire (US)DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not plannedNYSE:JNJJohnson and Johnson
27/09/202409:05PR Newswire (US)Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary diseNYSE:JNJJohnson and Johnson
27/09/202409:00PR Newswire (US)TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myelomaNYSE:JNJJohnson and Johnson
23/09/202407:32IH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNYSE:JNJJohnson and Johnson
20/09/202419:53Business WireAttorneys Vow to Oppose J&J’s Third Bankruptcy AttemptNYSE:JNJJohnson and Johnson
20/09/202417:19Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
20/09/202416:43Business WireJohnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc ClaimsNYSE:JNJJohnson and Johnson
19/09/202419:54PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
17/09/202407:40IH Market NewsMicrosoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with AmazonNYSE:JNJJohnson and Johnson
16/09/202403:50PR Newswire (US)Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancerNYSE:JNJJohnson and Johnson
15/09/202403:30PR Newswire (US)New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancerNYSE:JNJJohnson and Johnson
14/09/202410:45PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancerNYSE:JNJJohnson and Johnson
14/09/202404:10PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancerNYSE:JNJJohnson and Johnson
12/09/202417:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
11/09/202419:22PR Newswire (US)TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel diseaseNYSE:JNJJohnson and Johnson
10/09/202418:15PR Newswire (US)Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)NYSE:JNJJohnson and Johnson
08/09/202414:47PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
05/09/202417:30Business WireJohnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsNYSE:JNJJohnson and Johnson
05/09/202407:11IH Market NewsQualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual ListingNYSE:JNJJohnson and Johnson
30/08/202416:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:JNJJohnson and Johnson
29/08/202415:05Edgar (US Regulatory)Form N-PX - Annual Report of proxy voting record of management investment companiesNYSE:JNJJohnson and Johnson
29/08/202409:00PR Newswire (US)Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravisNYSE:JNJJohnson and Johnson
27/08/202409:00PR Newswire (US)Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology CongressNYSE:JNJJohnson and Johnson
26/08/202409:58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:JNJJohnson and Johnson
26/08/202409:00Business WireJohnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024NYSE:JNJJohnson and Johnson
21/08/202409:12IH Market NewsWalmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest NewsNYSE:JNJJohnson and Johnson
20/08/202408:30Business WireJohnson & Johnson to Acquire V-WaveNYSE:JNJJohnson and Johnson
20/08/202408:00PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
15/08/202407:05IH Market NewsGoogle Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
 Apresentando as notícias mais relevantes sobre:NYSE:JNJ

Seu Histórico Recente

AMEX
IBHE
iShares iBonds 2025 Term...
TG
599A
Sands China
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados